MiR-145 inhibits the expression of multiple targets essential for sustained CRC growth such as insulin receptor substrate 1 (IRS-1), the proto-oncogene c-Myc, the proto-oncogene Yamaguchi sarcoma viral oncogen homolog 1 (YES-1), and signal transducers and activators of transcription 1 (STAT1) [31,32,33]. This evidence concerns the gene STAT1 and colorectal carcinoma.